A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

@inproceedings{Bentley2013ACA,
  title={A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom},
  author={Anthony F Bentley and Ivana Filipovic and Katherine L Gooch and Katharina Buesch},
  booktitle={Health economics review},
  year={2013}
}
BACKGROUND Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of hospitalisation with RSV in the United Kingdom (UK). METHODS A decision tree model was developed to reflect the clinical pathway of infants at… CONTINUE READING
10 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

NHS Reference costs; 2009

  • Department of Health
  • https://www.gov.uk/ government/publications/nhs…
  • 2010
Highly Influential
5 Excerpts

Unit Costs of Health and Social Care 2010. Canterbury, UK: Personal Social Services

  • L Curtis
  • Research Unit;
  • 2010
Highly Influential
5 Excerpts

NICE clinical guideline 117: Turberculosis; 2011

  • National Institute for Health, Clinical Excellence NICE
  • http://www.nice.org.uk/cg117
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…